Cerebrovascular reactivity to hypercapnia in patients with migraine: A dual‐echo arterial spin labeling MRI study
Headache: The Journal of Head and Face Pain · 2024
DOI: 10.1111/head.14680 ↗At a glance
Beobachtungsstudie in Headache: The Journal of Head and Face Pain, 2024. Written by E S Hoogeveen and 6 co-authors. Institution: Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands. Major MEDLINE topics: Epilepsy, Migraine without Aura. Cited 3 times so far (Crossref); 41 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: International Retinal Research Foundation, Stichting Dioraphte, Nederlandse Organisatie voor Wetenschappelijk Onderzoek.
Abstract (original language)
Objective
This study aimed to compare cerebrovascular reactivity between patients with migraine and controls using state‐of‐the‐art magnetic resonance imaging (MRI) techniques.
Background
Migraine is associated with an increased risk of cerebrovascular disease, but the underlying mechanisms are still not fully understood. Impaired cerebrovascular reactivity has been proposed as a link. Previous studies have evaluated cerebrovascular reactivity with different methodologies and results are conflicting.
Methods
In this single‐center, observational, case–control study, we included 31 interictal patients with migraine without aura (aged 19–66 years, 17 females) and 31 controls (aged 22–64 years, 18 females) with no history of vascular disease. Global and regional cerebrovascular reactivities were assessed with a dual‐echo arterial spin labeling (ASL) 3.0 T MRI scan of the brain which measured the change in cerebral blood flow (CBF) and BOLD (blood oxygen level dependent) signal to inhalation of 5% carbon dioxide.
Results
When comparing patients with migraine to controls, cerebrovascular reactivity values were similar between the groups, including mean gray matter CBF‐based cerebrovascular reactivity (3.2 ± 0.9 vs 3.4 ± 1% ΔCBF/mmHg CO 2 ; p = 0.527), mean gray matter BOLD‐based cerebrovascular reactivity (0.18 ± 0.04 vs 0.18 ± 0.04% ΔBOLD/mmHg CO 2 ; p = 0.587), and mean white matter BOLD‐based cerebrovascular reactivity (0.08 ± 0.03 vs 0.08 ± 0.02% ΔBOLD/mmHg CO 2 ; p = 0.621).There was no association of cerebrovascular reactivity with monthly migraine days or migraine disease duration (all analyses p > 0.05).
Conclusion
Cerebrovascular reactivity to carbon dioxide seems to be preserved in patients with migraine without aura.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.
- Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands.
- C.J. Gorter MRI Center, Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.
- Department of Radiology and Nuclear Medicine, Medisch Spectrum Twente, Enschede, The Netherlands.
- Department of Anesthesiology, Leiden University Medical Center, Leiden, The Netherlands.
Funding
- International Retinal Research Foundation
- Stichting Dioraphte
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
Cite
APA
Hoogeveen, E. S., Pelzer, N., Ghariq, E., van Osch, M. J. P., Dahan, A., Terwindt, G. M., & Kruit, M. C. (2024). Cerebrovascular reactivity to hypercapnia in patients with migraine: A dual‐echo arterial spin labeling MRI study. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14680
Vancouver
Hoogeveen ES, Pelzer N, Ghariq E, van Osch MJP, Dahan A, Terwindt GM, et al. Cerebrovascular reactivity to hypercapnia in patients with migraine: A dual‐echo arterial spin labeling MRI study. Headache: The Journal of Head and Face Pain. 2024. doi:10.1111/head.14680
BibTeX
@article{Hoogeveen2024,
author = {Hoogeveen, E S and Pelzer, N and Ghariq, E and van Osch, M J P and Dahan, A and Terwindt, G M and Kruit, M C},
title = {Cerebrovascular reactivity to hypercapnia in patients with migraine: A dual‐echo arterial spin labeling MRI study},
journal = {Headache: The Journal of Head and Face Pain},
year = {2024},
doi = {10.1111/head.14680}
}
EUVIMED